login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
OCUGEN INC (OCGN) Stock News
USA
-
Nasdaq
- NASDAQ:OCGN -
US67577C1053
-
Common Stock
1.21
USD
+0.05 (+4.31%)
Last: 12/3/2025, 8:00:02 PM
1.2098
USD
0 (-0.02%)
After Hours:
12/3/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
OCGN Latest News, Press Relases and Analysis
All
Press Releases
14 days ago - By: Ocugen
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
14 days ago - By: Ocugen
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
a month ago - By: The Motley Fool
Ocugen (OCGN) Q3 2025 Earnings Call Transcript
a month ago - By: Zacks Investment Research
- Mentions:
KMDA
Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates
a month ago - By: Ocugen
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
a month ago - By: Benzinga
- Mentions:
TECH
INSE
GEF
SKYT
...
Earnings Scheduled For November 5, 2025
3 months ago - By: Benzinga
Forecasting The Future: 4 Analyst Projections For Ocugen
a month ago - By: Ocugen
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
a month ago - By: Ocugen
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
a month ago - By: Ocugen
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
2 months ago - By: Ocugen
Ocugen to Present at Industry and Investor Conferences in October 2025
4 months ago - By: The Motley Fool
Ocugen (OCGN) Q2 Revenue Jumps 20%
2 months ago - By: Ocugen
Ocugen to Present at Industry and Investor Conferences in October 2025
3 months ago - By: Ocugen
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
3 months ago - By: Ocugen
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
3 months ago - By: Ocugen
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
3 months ago - By: Ocugen
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
3 months ago - By: Zacks Investment Research
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know
4 months ago - By: Ocugen
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
4 months ago - By: Ocugen
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
4 months ago - By: Ocugen
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
4 months ago - By: Ocugen
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
4 months ago - By: Ocugen
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
4 months ago - By: Ocugen
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
4 months ago - By: Zacks Investment Research
- Mentions:
CCCC
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
4 months ago - By: Ocugen
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
4 months ago - By: Ocugen
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
5 months ago - By: Ocugen
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
5 months ago - By: Ocugen
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
5 months ago - By: Ocugen
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
5 months ago - By: Ocugen
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
Please enable JavaScript to continue using this application.